A Prospective Observational Study of patients who switched from SGLT2 inhibitor tablets to luseogliflozin OD film formulation in terms of feeling, Efficacy and Safety of taking the medicine.
Not Applicable
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-UMIN000050476
- Lead Sponsor
- Seino internal Medicine Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients who changed from Lusefi OD film to Lusefi tablets or other SGLT-2 inhibitor tablets during the study period. (2)Patients who have changed or added other hypoglycemic drugs. (3)Patients who have their medications packaged in a single package.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) OHA-Q ver.2 after 1 month of switching 2) The change from baseline in HbA1c after 6 months of switching
- Secondary Outcome Measures
Name Time Method 1) Change over time from baseline in HbA1c up to 6 months after the switch 2) Change over time in the following items a) to d) up to 6 months after the switch a) 1.5-AG b) GA c) Liver enzymes(AST,ALT,GGT) d) Weight 3) Adherence(Pill Counting) 4) Stratified analysis of the following a) to c) a) By each SGLT2 inhibitor b) By patient background c) By medication adherence 5) OHA-Q ver.2 after 6 months of switching